Doctronic has announced a major funding boost, raising $40 million in a Series B round. The financing was co-led by Abstract and Lightspeed Venture Partners, with participation from existing investors including Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. This brings the company’s total funding to over $65 million. The new investment follows less than a year after its previous funding rounds and highlights the company’s rapid growth in the digital health space.

Impressive Growth and Market Impact

Since completing its Series A funding, Doctronic reports a 15-fold increase in revenue, reaching eight figures annually. The company has also nearly tripled its repeat patient rate and now attracts more than 300,000 unique visitors each week. These numbers reflect strong market demand and the company’s expanding footprint in healthcare technology.

What sets Doctronic apart is its focus on moving beyond basic AI tools that simply answer questions or handle administrative tasks. Instead, the company is positioning itself as a platform capable of actively participating in care delivery, especially in regulated environments. This shift marks a significant step forward in healthcare AI innovation.

Trailblazing in Autonomous Prescription Management

One of Doctronic’s key milestones was becoming the first AI-native platform to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox in December 2025. This achievement is notable because most AI health tools still operate mainly in informational or administrative roles. Doctronic claims its system can take responsibility for clinical outcomes in certain settings, with physician oversight and escalation protocols for complex cases.

Ramtin Naimi, a partner at Abstract, emphasizes the importance of this milestone. He believes it demonstrates that AI can improve healthcare outcomes at scale and that Doctronic’s clinical rigor and market demand are validated by its recent growth. Naimi also highlights the company’s willingness to take responsibility for health outcomes, which he sees as a sign of the future of healthcare delivery.

Plans for Expansion and Future Growth

With the new funding, Doctronic plans to broaden its reach into hospitals, academic institutions, digital health platforms, and insurance payers. The company is also looking to expand into pediatrics, an area with high consumer demand and limited access to care. CEO and co-founder Matt Pavelle says this round will help the company push further into these sectors while continuing to serve millions of consumers directly.

In addition, Doctronic is engaging with regulators outside Utah and exploring opportunities in other states. This indicates a move from a proof-of-concept in one region to a broader regulatory and commercial footprint. The goal is to make its AI-powered prescription services available on a larger scale and in more regulated environments.

The company was founded by Dr. Adam Oskowitz and Matt Pavelle. Based in New York, Doctronic claims to have built the first AI system trusted to make autonomous clinical decisions, operating independently within its own regulatory framework. This pioneering approach aims to transform how healthcare providers deliver care and manage patient outcomes with AI support.

Inspired by

• https://justainews.com/companies/funding-news/doctronic-raises-40m-series-b-for-ai-healthcare/